Fail Safe Cell Therapy


Author Archives: jasonashley

panCELLa is proud to announce Dr. Armand Keating recognized with Lifetime Achievement Award from Canadian Hematology Society

Dr. Keating has been unanimously chosen to receive the 2017 Lifetime Achievement Award by the Canadian Hematology Society (CHS). It is an even greater honour that Dr. Keating has been chosen to be the first recipient of this award that honours those who are internationally recognized for their work and impact in the field of hematology. Dr. Keating is also recognized as an outstanding hematologist who nurtures and encourages young faculty throughout Canada.

The inaugural presentation of this award will be held during the Canadian Hematology Society gala evening at ASH, on Sunday, December 10, 2017 at 7:00 p.m. at the Omni Hotel, 100 CNN Centre, Atlanta, GA.

panCELLa’s Dr. Nagy will be speaking on “a solution for cell therapy safety, paving the way to the clinic” at the 2nd Annual Medicine By Design (MbD) Symposium

December 5, 2017 – 8 am | Add to Google Calendar Toronto The MbD 2nd annual symposium brings together principal investigators and trainees from across the University of Toronto and partner hospitals, along with members of their Scientific Advisory Board and industry and government representatives, to share research and ignite new collaborations. The keynote speaker will be Donald… Continue Reading

panCELLa’s Dr. Nagy is an invited speaker at The 12th International Congress of Chinese Orthopaedic Association COA2017.

November 15-18, 2017, Zhuhai, China Dr. Nagy will be presenting on “Fail-Safe Cell and Gene Therapy” November 15th and 16th during the Innovation & Transformation Session at the 19 th Annual COA2017. The COA Conference provides a broad platform for academic exchanges highlighting new technologies and ideas. For further information: Continue Reading

Reprogramming Mouse Fibroblasts with piggyBac Transposons

In 2006, Shinya Yamanaka and his student Kazutoshi Takahashi showed that the expression of only four specific genes is sufficient to reprogram fully differentiated somatic cells into pluripotent stem cells. These cells, termed induced pluripotent stem (iPS) cells, share many of their characteristics with embryonic stem (ES) cells. In this protocol, we describe one of the simplest ways of generating iPS cells from mouse fibroblasts. It combines an efficient transposon-mediated transfection and the tetracycline-inducible system to control the expression of the Yamanaka reprogramming factors. Continue Reading